Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
Stocks · News reference
Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026
Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a Biologics License
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Invivyd shares are trading lower after the company announced topline data from the LIBERTY Phase 3, randomized, double-blind, active-controlled study evaluating the safety and tolerability of VYD2311.
8-K filing — Invivyd, Inc. (IVVD)
Filed: 2026-09-29 AccNo: 0001193125-26-406007 Size: 12 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and